MRMD · Marimed Inc.
Market Cap
$30.63M
Shares
403.04M
MRMD metrics
71 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.08
Market cap
$30.63M
Price action
19 metricsPrice change (1W)
-11.6%
Price change (30D)
+21.0%
Price change (3M)
-2.3%
Price change (6M)
-2.3%
Price change (YTD)
-18.9%
Price change (1Y)
-50.5%
Trailing year
Price change (5Y)
-92.2%
52-week high
$0.18
52-week low
$0.06
Change from 52-week high
-57.7%
Change from 52-week low
+21.0%
Annualized volatility
92.9%
Beta
0.3
RSI (14D)
51.9
Price vs SMA 50
+9.3%
Price vs SMA 200
-4.4%
Avg volume (3M)
483,227
Relative volume
0.8
Average dollar volume
$35,734
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
403.04M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.2×
reciprocal yield 534.8%
P / book
0.7
reciprocal yield 141.2%
FCF yield
26.1%
TTM · current market cap
Buyback yield
—
P / FCF
3.8
reciprocal yield 26.1%
P / operating cash flow
3.3
reciprocal yield 30.3%
Earnings yield
-48.9%
Historical valuation
8 metricsP / E historical average (3Y)
22.4×
reciprocal yield 4.5%
P / E historical average (5Y)
22.4×
reciprocal yield 4.5%
EV / revenue historical average (3Y)
0.8×
reciprocal yield 131.9%
EV / revenue historical average (5Y)
1.1×
reciprocal yield 87.8%
EV / EBIT historical average (3Y)
274.7×
reciprocal yield 0.4%
EV / EBIT historical average (5Y)
182.6×
reciprocal yield 0.5%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-13
Profitability
9 metricsGross margin
35.6%
Operating margin
-1.5%
Trailing 12 months
Net margin
-9.1%
Gross profit (TTM)
$58.37M
Operating profit (TTM)
−$2.38M
Net income (TTM)
−$14.98M
Trailing 12 months
Diluted EPS (TTM)
$-0.05
FCF margin
4.9%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+6.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$163.82M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.5%
Year over year · more shares
Revenue CAGR (3Y)
+6.0%
Revenue CAGR (5Y)
+25.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-34.7%
Return on assets
-7.6%
Debt / equity
—
Current ratio
0.9
EBITDA (TTM)
$6.29M
Free cash flow (TTM)
$8.01M
Quick ratio
0.3
Interest coverage
-0.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$8.44M
Total assets
$197.23M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
$9.27M
Capital expenditures (TTM)
$1.26M
R&D (TTM)
—
SG&A (TTM)
$960,640
Stock compensation (TTM)
$1.44M
R&D / revenue
—
Stock compensation / revenue
0.9%
Ownership (13F)
3 metrics13F filers
2
13F filer change QoQ
-1
Institutional ownership
0.2%
Short interest
3 metricsShort interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
42 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—